Intelligent Bio Solutions INC 8-K filings

Intelligent Bio Solutions Inc. announced the completion of its multi-site Method Comparison Study for the Intelligent Fingerprinting Drug Screening System, a crucial step for its FDA 510(k) submission.

Intelligent Bio Solutions Inc. announced the completion of a Usability Study for its Intelligent Fingerprinting Drug Screening System, a crucial step supporting its FDA 510(k) submission for U.S. market clearance.

Intelligent Bio Solutions Inc. announced the completion of its Interference Study for the Intelligent Fingerprinting Drug Screening System, a crucial step towards FDA 510(k) submission for U.S. market clearance.

Intelligent Bio Solutions Inc. announced an updated total of 3,018,188 outstanding common shares as of July 31, 2026, resulting from recent stock sales, warrant exercises, and advisory agreements.

Intelligent Bio Solutions Inc. announced it has resolved all cybersecurity and software-related review items for its upcoming FDA 510(k) submission, positioning it for a planned U.S. market entry.

Intelligent Bio Solutions Inc. announced the completion of precision testing for its Intelligent Fingerprinting Drug Screening System, a crucial step towards FDA 510(k) submission for U.S. market clearance.

Intelligent Bio Solutions Inc. has launched an Interference Study to support its FDA 510(k) submission for U.S. market clearance of its Intelligent Fingerprinting Drug Screening System for opiate codeine detection.

Intelligent Bio Solutions Inc. has initiated a multi-site Method Comparison Study to support its FDA 510(k) submission for U.S. market clearance of its Intelligent Fingerprinting Drug Screening System for opiate codeine.

Intelligent Bio Solutions Inc. provided an investor presentation on April 20, 2026, detailing business operations and an update on outstanding shares.

Intelligent Bio Solutions Inc. grants restricted stock awards to executives, directors, and employees, while updating its At-The-Market offering capacity.

Intelligent Bio Solutions announced the successful deployment of its first drug screening readers from its new manufacturing partner, Syrma Johari, and doubled in-house test strip production, positioning for U.S. market entry.

Intelligent Bio Solutions Inc. announced record fiscal second quarter revenue growth of 48% year-over-year, driven by a 104% surge in reader sales and a 33% increase in cartridge sales.

Intelligent Bio Solutions Inc. announced preliminary unaudited fiscal second quarter 2026 revenue growth of approximately 48% year-over-year, driven by strong reader and cartridge sales.

Intelligent Bio Solutions Inc. has commenced clinical studies to support a new FDA 510(k) submission for its fingerprint drug screening system for codeine detection, targeting the multi-billion dollar U.S. market.

Intelligent Bio Solutions Inc. announced it has regained compliance with Nasdaq's minimum bid price requirement, closing the matter with the exchange.

Intelligent Bio Solutions Inc. closed a $10.0 million private placement of common stock and warrants to fund working capital and strategic initiatives.

Intelligent Bio Solutions Inc. announced a new manufacturing partnership with Syrma Johari MedTech to strengthen global production capability and increase gross margins by approximately 20 percentage points.

Intelligent Bio Solutions Inc. received a Nasdaq deficiency notice for its stock price and implemented a 1-for-10 reverse stock split to regain compliance.

Intelligent Bio Solutions Inc. announced a 1-for-10 reverse stock split to become effective on December 15, 2025, aiming to adjust its share structure.

Intelligent Bio Solutions Inc. has made an investor presentation available on its website, detailing its business and operations.

Intelligent Bio Solutions Inc. issued 75,000 restricted common shares to MDM Worldwide Solutions Inc. as compensation for strategic communication advisory services.

Intelligent Bio Solutions Inc. announced record first-quarter fiscal 2026 revenue of $1.11 million, driven by strong cartridge sales and strategic market expansion, despite an increased net loss.

Intelligent Bio Solutions Inc. announced preliminary, unaudited record revenue exceeding $1 million for fiscal first quarter 2026, marking a 32% sequential and 28% year-over-year increase.

Intelligent Bio Solutions Inc. announced a 50% year-over-year increase in new customer accounts, adding 33 in its fiscal first quarter and bringing total active accounts to over 480.

Intelligent Bio Solutions Inc. stockholders approved an expanded long-term incentive plan and authorized a potential reverse stock split to maintain Nasdaq listing compliance.

Intelligent Bio Solutions Inc. announced a revised timeline for FDA 510(k) clearance of its fingerprint drug screening system, now anticipated in H2 2026.

Intelligent Bio Solutions Inc. has extended the termination date for its Series H-1 Common Stock Purchase Warrants from September 27, 2025, to March 27, 2026, with no change to exercise prices or other terms.

Intelligent Bio Solutions Inc. announced a delay in FDA 510(k) clearance for its fingerprint drug screening system, requiring a new submission.

Intelligent Bio Solutions Inc. announced its fiscal 2025 fourth quarter and full-year results, highlighting progress on U.S. market expansion and revenue growth in Q4, despite a full-year net loss increase and significant cash reduction.

Intelligent Bio Solutions Inc. announced preliminary fiscal fourth quarter 2025 revenue growth of approximately 16% sequentially and year-over-year, alongside significant progress on U.S. FDA 510(k) clearance for its opiate test system.